| 抗新型冠状病毒潜力药物——瑞德西韦 |
| |
| 引用本文： | 徐子金,王平. 抗新型冠状病毒潜力药物——瑞德西韦[J]. 中国现代应用药学, 2020, 37(3): 264-268 |
| |
| 作者姓名： | 徐子金 王平 |
| |
| 作者单位： | 浙江工业大学,浙江工业大学 |
| |
| 摘 要： | 当前,新型冠状病毒(2019-n Co V)感染引发的肺炎疫情已经发展为严重的公共卫生安全问题。针对该病毒,目前临床上并没有针对性的抗病毒药物。瑞德西韦(remdesivir,GS-5734)是由美国吉利德科学公司(Gilead Science)研制的一种新型核苷酸类似物抗病毒药。由于瑞德西韦在抗同属冠状病毒的非典型性肺炎冠状病毒(SARS-Co V)和中东呼吸综合症冠状病毒(MERS-Co V)中表现出较好的作用,一项针对其抗2019-nCoV的临床试验已经在中国启动。本文就该药物的基本信息、作用机制、药动学、国内外研究现状等方面进行概述,以期为临床用药提供参考。
|
| 关 键 词： | 新型冠状病毒 瑞德西韦 临床研究 |
| 收稿时间： | 2020-02-05 |
| 修稿时间： | 2020-02-07 |
Potential Anti 2019-nCoV Drug: Remdesivir |
| |
| XU Zijin and WANG Ping. Potential Anti 2019-nCoV Drug: Remdesivir[J]. The Chinese Journal of Modern Applied Pharmacy, 2020, 37(3): 264-268 |
| |
| Authors: | XU Zijin and WANG Ping |
| |
| Affiliation: | Zhejiang University Of Technology,Zhejiang University Of Technology |
| |
| Abstract: | ABSTRACT: At present, the pneumonia caused by the novel coronavirus (2019-nCoV) infection has developed into a serious public health and safety problem. Currently, there is no targeted antiviral drugs for the virus. Remdesivir (GS-5734) is a new nucleotide analogue antiviral drug developed by Gilead science. The targeted clinical trials against 2019-CoV have been launched in China as remdesivir has shown a good effect in anti SARS-CoV and MERS-CoV. In this paper, the basic information, mechanism of action, pharmacokinetics, research status in domestic and international of remdesivir are summarized in order to provide reference for clinical medication. |
| |
| Keywords: | 2019-nCoV Remdesivir Clinical research |
| 本文献已被 维普 等数据库收录！ |
| 点击此处可从《中国现代应用药学》浏览原始摘要信息 |
|
点击此处可从《中国现代应用药学》下载全文 |
|
